Current stock page

Financial Data

PRCT Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareMedical - DevicesScore data as of Nov 18, 2026

PRCTPROCEPT BioRobotics Corporation

Healthcare / Medical - Devices

Low Priority

In Line With Peers

BearishEdge 5/10
$25.18+$1.40 (+5.89%)

Latest quote

  • Momentum
    60
  • Value
    38
  • Quality
    45
  • Risk resilience
    45
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

Latest Quarter at a Glance

Quarter ended Sep 30, 2026, compared with the same quarter a year earlier.

Revenue
$98.29M
+18.0% YoY
Net income
-$26.52M
−23.8% YoY
Free cash flow
-$9.65M
−1.6% YoY
Operating margin
-27.9%
−0.0 pts YoY

Quarterly Financial Statements

Updated Nov 19, 2026.

PRCT, last 8 quarters. YoY compares the latest quarter with the same quarter a year earlier.

Income statement
Income statement, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Revenue+18.0%$98M$94M$83M$76M$83M$79M$69M$68M
Gross profit+24.4%$65M$62M$54M$46M$52M$50M$44M$44M
Operating income−18.0%−$27M−$27M−$33M−$31M−$23M−$22M−$27M−$20M
Net income−23.8%−$27M−$27M−$32M−$30M−$21M−$20M−$25M−$19M
EPS (diluted)−21.1%−$0.46−$0.47−$0.56−$0.53−$0.38−$0.35−$0.45−$0.35
Gross margin+3.4 pts66.3%66.0%64.9%60.6%62.9%63.3%63.9%64.0%
Operating margin−0.0 pts-27.9%-29.0%-39.2%-40.6%-27.8%-28.0%-39.7%-28.9%
Net margin−1.3 pts-27.0%-28.4%-38.1%-39.1%-25.7%-24.7%-35.8%-27.6%
Cash flow
Cash flow, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Operating cash flow−35.4%−$9M−$57M−$38M−$10M−$7M−$15M−$17M−$32M
Capital expenditure+76.7%−$667K−$6M−$3M−$2M−$3M−$3M−$2M−$1M
Free cash flow−1.6%−$10M−$63M−$41M−$12M−$10M−$18M−$19M−$34M
Free cash flow margin+1.6 pts-9.8%-66.9%-49.4%-15.9%-11.4%-22.5%-27.2%-49.2%
Balance sheet
Balance sheet, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
Total assets−7.4%$474M$479M$487M$508M$512M$513M$519M$534M
Total liabilities+10.4%$145M$139M$139M$142M$131M$127M$130M$132M
Shareholders' equity−13.5%$329M$340M$348M$366M$380M$386M$389M$402M
Total debt−2.5%$77M$78M$78M$78M$79M$79M$80M$80M
Cash and equivalents−25.8%$218M$228M$246M$287M$294M$303M$316M$334M
Valuation and ratios
Valuation and ratios, last 8 quarters, newest first
MetricTrendYoYSep '26Jun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24
P/B ratio−1.103.533.213.913.624.635.697.858.70
Return on equity−12.7 pts-34.9%-32.3%-29.5%-26.1%-22.2%-21.8%-23.2%-22.7%
Debt to equity+0.030.230.230.220.210.210.210.210.20
Free cash flow yield−6.3 pts-10.9%-11.5%-5.9%-4.4%-4.5%-4.1%-2.9%-3.0%

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
P/E ratio-11.77x
P/B ratio4.14x
Revenue growth (YoY)17.96%
EPS growth (YoY)-21.05%
Gross margin64.66%
Operating margin-33.61%
ROE-33.23%
ROIC-29.16%
Debt to equity0.23
FCF yield-9.22%

As of Nov 18, 2026

Technical indicators
MetricValue
Close
As of Nov 18, 2026
$25.18
Volume
As of Nov 13, 2026
1.68M
RSI (14)
As of Nov 13, 2026
69.03
MACD
As of Nov 13, 2026
1.16
MACD signal
As of Nov 13, 2026
0.75
MACD histogram
As of Nov 13, 2026
0.41
ADX (14)
As of Nov 13, 2026
36.66
SMA (50)
As of Nov 13, 2026
$19.52
SMA (200)
As of Nov 13, 2026
$22.91
ATR (14)
As of Nov 13, 2026
$1.33
Historical volatility (annualized)
As of Nov 13, 2026
63.96%
Volume (20-day average)
As of Nov 13, 2026
1.32M
Risk measures
MetricValue
Resilience score45/100
Beta1.01
Annual volatility65.89%
Max drawdown-53.77%
Sharpe ratio-0.11
VaR (95%, 1-day)-5.96%

As of Nov 18, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

PRCT Financial Data FAQ

What is PROCEPT BioRobotics Corporation's revenue?

PROCEPT BioRobotics Corporation's revenue is one of the core financial data points for PRCT. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is PROCEPT BioRobotics Corporation's revenue growing?

Revenue growth shows whether PROCEPT BioRobotics Corporation is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is PRCT's EPS?

PRCT's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is PROCEPT BioRobotics Corporation's net income?

PROCEPT BioRobotics Corporation's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does PROCEPT BioRobotics Corporation generate?

Free cash flow shows how much cash PROCEPT BioRobotics Corporation generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does PROCEPT BioRobotics Corporation have?

Cash and debt help frame PRCT's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.